FT
VRTX icon

Fiduciary Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Fiduciary Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.88M Sell
19,876
-156
-0.8% -$72.7K 0.1% 118
2025
Q4 		$9.08M Sell
20,032
-1,889
-9% -$814K 0.1% 116
2025
Q3 		$8.59M Buy
21,921
+4,402
+25% +$1.84M 0.1% 123
2025
Q2 		$7.8M Buy
17,519
+255
+1% +$118K 0.1% 126
2025
Q1 		$8.37M Buy
17,264
+4,104
+31% +$1.91M 0.11% 111
2024
Q4 		$5.3M Buy
13,160
+1,147
+10% +$532K 0.07% 157
2024
Q3 		$5.59M Buy
12,013
+2,183
+22% +$1.05M 0.08% 155
2024
Q2 		$4.61M Buy
9,830
+1,209
+14% +$525K 0.07% 160
2024
Q1 		$3.6M Buy
8,621
+1,369
+19% +$579K 0.06% 186
2023
Q4 		$2.95M Buy
7,252
+2,553
+54% +$943K 0.05% 204
2023
Q3 		$1.63M Buy
4,699
+149
+3% +$52.1K 0.03% 255
2023
Q2 		$1.6M Buy
4,550
+264
+6% +$89K 0.03% 262
2023
Q1 		$1.35M Sell
4,286
-160
-4% -$48K 0.03% 279
2022
Q4 		$1.28M Buy
4,446
+331
+8% +$101K 0.03% 299
2022
Q3 		$1.19M Buy
4,115
+689
+20% +$198K 0.03% 291
2022
Q2 		$966K Buy
3,426
+219
+7% +$58.6K 0.02% 334
2022
Q1 		$837K Buy
+3,207
New +$761K 0.02% 378
2021
Q4 		– Sell
-2,858
Closed -$519K – 669
2021
Q3 		$519K Sell
2,858
-65
-2% -$12.7K 0.01% 472
2021
Q2 		$590K Sell
2,923
-322
-10% -$67.4K 0.01% 433
2021
Q1 		$697K Buy
3,245
+1,172
+57% +$257K 0.01% 398
2020
Q4 		$490K Buy
+2,073
New +$476K 0.01% 432
2019
Q3 		– Sell
-2,333
Closed -$428K – 521
2019
Q2 		$428K Buy
2,333
+1,200
+106% +$210K 0.01% 372
2019
Q1 		$209K Buy
+1,133
New +$209K 0.01% 458
2018
Q4 		– Sell
-1,162
Closed -$224K – 469
2018
Q3 		$224K Buy
+1,162
New +$207K 0.01% 444

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fiduciary Trust's VRTX Position: Q1 2026 in Review

Fiduciary Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 0.78% in Q1 2026, selling an estimated $72.7K and leaving 19,876 shares worth $8.88M. The position accounts for 0.1% of the portfolio, ranked #118.

Fiduciary Trust first reported a position in VRTX in Q3 2018 and has held it in 24 quarters since. The position peaked at $9.08M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fiduciary Trust held 19,876 shares of Vertex Pharmaceuticals worth $8.88M as of Q1 2026.
  • Fiduciary Trust sold 156 Vertex Pharmaceuticals shares in Q1 2026, an estimated $72.7K.
  • Vertex Pharmaceuticals made up 0.1% of Fiduciary Trust's portfolio in Q1 2026, its #118 holding.
  • Fiduciary Trust first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 24 quarters since.
  • Fiduciary Trust's Vertex Pharmaceuticals position peaked at $9.08M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.